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Growth and remodeling of lymphatic vasculature in the tu-mor microenvironment may be supported by a variety of 
growth factors that stimulate cognate receptors on host lym-
phatic vessels.1,2 The process has been shown to contribute to 
lymph node metastasis.3–5 It is also known that a dominant pro-
lymphangiogenic growth factor, vascular endothelial growth 
factor (VEGF-C), is frequently overexpressed in primary car-
cinomas. Along with a unique role in driving developmental 
lymphangiogenesis,2,6 VEGF-C also plays critical roles in tu-
mor lymphangiogenesis along with the stimulatory actions of 
other tumor vascular growth effectors, such as VEGF-A and 
fibroblast growth factor-2 ,as well as cytokines.6,7
Heparan sulfate is a linear glycan polymer expressed on a 
variety of proteoglycans, which plays important roles in endo-
thelial growth factor binding in unique pathological contexts, 
including tumor angiogenesis.8–10 Heparan sulfate proteogly-
cans (HSPGs) secreted into tumor matrix may release growth 
factors on the action of tumor heparinase, mobilizing banks of 
proangiogenic factors bound to sulfated domains on heparan 
sulfate in tumor matrix.11,12 Endothelial-surface proteoglycans 
Cellular Biology
Circulation Research is available at http://circres.ahajournals.org DOI: 10.1161/CIRCRESAHA.116.308504
Rationale: Lymphatic vessel growth is mediated by major prolymphangiogenic factors, such as vascular endothelial 
growth factor (VEGF-C) and VEGF-D, among other endothelial effectors. Heparan sulfate is a linear polysaccharide 
expressed on proteoglycan core proteins on cell membranes and matrix, playing roles in angiogenesis, although 
little is known about any function(s) in lymphatic remodeling in vivo.
Objective: To explore the genetic basis and mechanisms, whereby heparan sulfate proteoglycans mediate pathological 
lymphatic remodeling.
Methods and Results: Lymphatic endothelial deficiency in the major heparan sulfate biosynthetic enzyme 
N-deacetylase/N-sulfotransferase-1 (Ndst1; involved in glycan-chain sulfation) was associated with reduced 
lymphangiogenesis in pathological models, including spontaneous neoplasia. Mouse mutants demonstrated 
tumor-associated lymphatic vessels with apoptotic nuclei. Mutant lymphatic endothelia demonstrated impaired 
mitogen (Erk) and survival (Akt) pathway signaling and reduced VEGF-C–mediated protection from starvation-
induced apoptosis. Lymphatic endothelial-specific Ndst1 deficiency (in Ndst1f/fProx1+/CreERT2 mice) was sufficient to 
inhibit VEGF-C–dependent lymphangiogenesis. Lymphatic heparan sulfate deficiency reduced phosphorylation 
of the major lymphatic growth receptor VEGF receptor-3 in response to multiple VEGF-C species. Syndecan-4 
was the dominantly expressed heparan sulfate proteoglycan in mouse lymphatic endothelia, and pathological 
lymphangiogenesis was impaired in Sdc4(−/−) mice. On the lymphatic cell surface, VEGF-C induced robust 
association between syndecan-4 and VEGF receptor-3, which was sensitive to glycan disruption. Moreover, VEGF 
receptor-3 mitogen and survival signaling was reduced in the setting of Ndst1 or Sdc4 deficiency.
Conclusions: These findings demonstrate the genetic importance of heparan sulfate and the major lymphatic 
proteoglycan syndecan-4 in pathological lymphatic remodeling. This may introduce novel future strategies to alter 
pathological lymphatic-vascular remodeling.  (Circ Res. 2016;119:210-221. DOI: 10.1161/CIRCRESAHA.116.308504.)
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may act in cis in a cell-autonomous manner or in trans to 
promote endothelial proliferation in response to growth fac-
tors.10,13 Although less is known with respect to lymphatic bi-
ology, preliminary work points to a role for heparan sulfate 
in VEGF-C–dependent proliferation of lymphatic endothelial 
cells (LECs) in culture.14 However, the genetic importance, 
mechanisms, and proteins involved in vivo remain poorly 
understood.
We generated lymphangiogenesis models in mice bear-
ing a lymphatic deficiency in the heparan sulfate biosynthetic 
enzyme N-deacetylase/N-sulfotransferase-1 (Ndst1), involved 
in initiating sulfate modifications of nascent heparan sulfate 
chains.8 We demonstrate that lymphangiogenesis is inhibited in 
models of oil granuloma–induced lymphangiogenesis, wound 
inflammation, and carcinomas on the Ndst1 mutant back-
ground, including VEGF-C–dependent lymphangiogenesis 
on a stringent lymphatic-specific Ndst1-deficient background. 
The mutation is associated with defects in lymphatic mito-
gen and survival signaling, and VEGF receptor-3 (VEGFR-3) 
phosphorylation in response to VEGF-C. Using proteoglycan 
expression analyses, gene-targeted mice and primary-cell 
mechanistic analyses, we further highlight syndecan-4 (Sdc4) 
as a major HSPG coreceptor required for VEGF-C mitogen 
and survival signaling, which complexes with VEGFR-3 in a 
glycan-dependent manner on VEGF-C exposure.
Methods
Cells and Cell Lines
Primary LECs were isolated from mouse mesenteric oil granuloma/
lymphangiomas, as previously described,15 and tested for LYVE-1/
podoplanin expression.14 For some studies, LECs were purified from 
lungs of Ndst1f/fTekCre+ mutants.16 Primary human lung LEC (hLEC; 
Lonza; previously shown >99% pure at third passage by Prox1 stain-
ing) were also used. For Lewis lung carcinoma (LLC) models, retrovi-
ruses expressing pLTR-mVEGFC-GFP were used to transduce LLCs 
(kindly provided by G. Thurston; Regeneron) with full-length VEGF-C 
(LLC-VC cells),17 or GFP-expressing empty vector (LLC-ev) cells as 
controls. The mouse transformed mesenteric LEC line (svLEC)18 was 
kindly obtained from Dr Alexander (LSU Health Sciences Center).
Mice and Pathological Lymphatic Proliferation Models
Details on mouse models targeting lymphangiogenesis in Ndst1 and 
Sdc4 mutants, including relevant references, are presented in the 
expanded Online Data Supplement.
Pathological Tissue Processing and Analysis
Tumor/tissue specimens were formalin-fixed, paraffin-embedded, 
and hematoxylin and eosin stained, with immunostaining details out-
lined in the Online Data Supplement.
Flow Cytometry
Lung digests were filtered through 100-μm strainers (Fisher), sub-
jected to red-cell lysis (eBioscience), and stained with PE-labeled 
antimouse podoplanin (eBioscience) and APC-labeled antimouse 
LYVE-1 (R&D), with Aqua (Biolegend) viability marker for dead-
cell exclusion. Dual PE/APC+ live cells were analyzed by an LSRII 
(BD) cytometer. The quantity of dual-positive cells as a percentage of 
total cells was analyzed/plotted and used in statistical analyses com-
paring lungs from mutant versus control mice.
Quantitative Polymerase Chain Reaction Analyses
RNA was isolated from primary LECs, reverse transcribed 
(Superscript III, Invitrogen), amplified using gene-specific primers to 
each core protein, and quantified (triplicate assays) using the 2−ΔΔCt 
method relative to β-actin. Primers included those for mouse HSPGs 
(Online Table I). For Ndst, the same method was used with primers 
for mouse Ndst1–Ndst4 isoenzymes.14
siRNA Transfections
Primary hLEC at near confluence were transfected with siRNA 
targeting heparan sulfate biosynthetic enzymes xylosyltransferase 
2 (XylT2; siXylT2) or Ndst1 (siNdst1), the HSPG core protein 
Sdc-4 (siSdc4), or receptors VEGFR-2 (siVEGFR-2) or VEGFR-3 
(siVEGFR-3); with scrambled-duplex RNA mock transfectants 
(siDS) as controls. Transfections (20-nmol/L siRNA) were car-
ried out using Lipofectamine (Invitrogen) after manufacturer rec-
ommendations. Transfection complex was added in Opti-Mem 
(Gibco), and incubated for 6 hours, with cell recovery overnight in 
normal growth medium.
VEGF-C Species
Human recombinant mature VEGF-C was purchased (R&D). 
Untagged pro–VEGF-C was expressed from full-length cDNA us-
ing a chinese hamster ovary dhfr gene-amplification system.19 This 
was predominantly a mixture of unprocessed and partially processed 
propeptide forms of VEGF-C. Highly expressed clones were iden-
tified by the ability of the culture supernatant to sustain growth of 
VEGFR-3/EpoR Ba/F3 cells.20 The affinity of pro–VEGF-C for hepa-
rin was used in the capture step from serum-free culture supernatant 
(salt elution from heparin-sepharose column at 0.48 M NaCl, with 
minor peak at 0.53 M). Cation exchange chromatography (pH 6.6) 
and gel filtration were used to increase prep homogeneity. Identity 
was confirmed by Western blotting. A short form of VEGF-C consist-
ing of minimum-binding domain residues A112-L215 was prepared 
as a strep-II–tagged protein in drosophila S2 cells and purified using 
streptactin resin. It did not bind to heparin. A mutant form of human 
VEGF-C (VEGF-CCys156Ser R&D) that binds exclusively to VEGFR-3 
was used in some studies.
Immunoblotting
Detailed methods for Western blotting of lysates after VEGF-C stim-
ulation of LECs are reported in the Online Data Supplement.
Receptor Tyrosine Kinase Phospho Arrays
Serum-starved hLEC were stimulated ± pro–VEGF-C (1 μg/mL) 
for 15 minutes. Lysates from 6-well plates were collected in 500-
μL Lysis Buffer (R&D Phospho-RTK Array–assay instructions) and 
cleared with supernatant used in receptor tyrosine kinase-assay after 
manufacturer protocol. After blocking, diluted lysates were incubated 
with slide arrays (4°C overnight) and washed, and antiphosphotyro-
sine horseradish peroxidase–tagged antibody was added (2 hours at 
room temperature), followed by wash, chemiluminescent develop-
ment, and digital-imaging densitometry. Further array details, in-
cluding incorporation of mitogen-activated protein kinase array after 
VEGF-C stimulation, are described in the Online Data Supplement.
Nonstandard Abbreviations and Acronyms
HSPG heparan sulfate proteoglycan
hLEC human lung LEC
LEC lymphatic endothelial cells
LLC Lewis lung carcinoma
LVD lymphatic vessel density
Ndst N-deacetylase/N-sulfotransferase
PLA proximity ligation assay
Sdc4 syndecan-4
siDS siRNA duplex scrambled control
VEGF vascular endothelial growth factor
VEGFR-2 VEGF receptor-2
VEGFR-3 VEGF receptor-3
XylT2 xylosyltransferase 2
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VEGFR-3 Phosphorylation Assays
Serum-starved cells were treated with VEGF-C species (1 µg/mL) and 
assayed using a human phospho-VEGFR3 Elisa Kit (R&D). Treated 
cells were lysed (R&D lysis buffer; 30 minutes, 4°C), spun-down, 
diluted, added to a precoated anti–VEGFR-3 plate overnight (4°C), 
followed by antiphosphotyrosine horseradish peroxidase (included 
in Kit). Biotin anti–VEGFR-3 (Reliatech) labeled with streptavidin-
horseradish peroxidase (Vector) was added to detect total VEGFR3. 
After incubating in substrate solution (R&D), reactions were stopped 
with 2N sulfuric acid. Plates were assayed at absorbance A450 nm, 
with values corrected against total VEGFR-3.
Proximity Ligation Assays
Chamber slides (Lab-Tek) coated with 50-μg/mL PurCol (Advanced 
Biomatrix), layered with serum-starved hLEC were stimulated with 
human mature VEGF-C (R&D) for 5 minutes ± pre treatment with 
heparinase in some experiments. Cells were fixed in ice-cold methanol 
for 10 minutes and blocked (Olink PLA-blocking reagent; 30 minutes 
at 37°C). Rabbit antihuman VEGFR-3 (Reliatech; or for some stud-
ies, anti–VEGFR-2; Cell Signaling) and goat antihuman Sdc-4 (R&D) 
were then added (2 µg/mL) together (in blocking solution overnight; 
4°C). After wash, Rabbit(−) and Goat(+) PLA Probes (Duolink assay; 
Olink Bioscience) were added (1:10 dilution). In other experiments, 
rabbit anti–VEGFR-3 was paired with either mouse antihuman Sdc-1 
(Abcam) or mouse antihuman Sdc-2 (kind gift from G. David) anti-
bodies. Antibodies were directed against extracellular domains, as per 
manufacturer protocol (imaging: 40× objective, room temperature).
Statistics
Mean values (±SD) were obtained for lymphatic vessel density 
(LVD) or apoptotic body index for each genotype. For some analy-
ses, means were compared using Student t test, with normalization 
to wild-type (or control) baseline values. Paired t tests were applied 
for comparing means of paired values (eg, for multiple experiments 
examining western phosphorylation responses pre- versus post–
VEGF-C species in siRNA versus control-transfected cells; compar-
isons of change in caspase signal in response to VEGF-C in siRNA 
versus control-transfected cells). For some experiments in which bi-
nary-type response data were examined (eg, terminal deoxynucleo-
tidyl transferase dUTP nick-end labeling [TUNEL] positivity versus 
negativity of lymphatic vessels or the presence versus the absence of 
LYVE-1/podoplanin dual-positive cells in flow cytometry analyses 
of tumor LECs) the Wald χ2 statistic was used. Two-way ANOVA 
was used in the analyses for experiments in which the significance of 
any interaction between genotype and biological response to growth 
factor (eg, VEGF-C–dependent lymphangiogenesis) was examined.
A 2-way ANOVA was also applied to assess for phospho–VEG-
FR-3 responses to VEGF-C as they depend on siRNA status and 
lymphatic endothelial PLA responses to VEGF-C as they depend on 
treatment ± heparinase. SPSS version 19, general linear model func-
tion, was used to compute these ANOVAs. A P value of ≤0.05 was 
considered significant for all analyses.
Results
Endothelial Mutation Resulting in Lymphatic Ndst1 
Deficiency Is Associated With Reduced Pathological 
Lymphangiogenesis and Altered Lymphatic 
Signaling
We assessed lymphangiogenesis in models of granulomatous 
inflammation, wound inflammation, and tumor lymphatic re-
modeling on the Ndst1f/fTekCre+ mutant background. We first 
used an established model of oil granuloma/lymphangioma in-
duction in the mouse abdomen,15 wherein plaque-like lesions 
develop intense proliferation of LYVE-1+ lymphatic endothe-
lium expressing VEGFR-3/Flt-4.15,21 In this model, although 
the Ndst1 mutation exists in all endothelia, lesion-associated 
LYVE-1+ vessel density in Ndst1f/fTekCre+ mutants was reduced 
(Figure 1A), suggesting that lymphatic Ndst1 deficiency af-
fected pathological lymphangiogenesis. Wound lymphangio-
genesis associated with early skin-wound remodeling was also 
reduced on the mutant background (Figure 1B). To examine 
tumor lymphangiogenesis, we crossed mutants with an MMTV-
PyMT spontaneous mammary tumor strain. Tumors demon-
strated reduced LVD in Ndst1f/fTekCre+ mutants (Figure 1C, top 
left). Tumor expression of VEGF-C was confirmed (Figure 1C, 
top right). TekCre transgene expression is pan-endothelial, and 
studies quantifying blood-vascular angiogenesis in the mutants 
(not shown) revealed a 67% reduction in tumor blood-vascular 
density relative to wild-type by CD105 staining (P<0.001) and 
50% reduction by CD31 (P<0.01). The unique effect of mu-
tation on LYVE-1+ vessel-density coupled with marked tumor 
VEGF-C production prompted us to further explore the effect 
of altered lymphatic heparan sulfate on VEGF-C–mediated 
lymphangiogenesis. As a developmental baseline, LVD in the 
ear bud of newborn mice, which is uniquely VEGF-C depen-
dent,2 was modestly reduced in Ndst1f/fTekCre+ mutants (Online 
Figure IA). Although the LVD reduction was significant, this 
did not result in obvious lymphatic developmental defects, such 
as limb edema or chylous ascites. Knockdown of Ndst1 in pri-
mary lung LECs from nonchallenged mutants was confirmed 
by quantitative polymerase chain reaction (Online Figure IB).
Lymphatic vessels in tumors from MMTV-PyMT Ndst1f/
fTekCre+ mutants were characterized by a greater percentage 
of lymphatic-associated TUNEL+ apoptotic bodies (Figure 1C, 
bottom). In separate primary human cell–based studies, we 
questioned whether altered heparan sulfate biosynthesis might 
impair VEGF-C–mediated protection of primary hLECs from 
apoptotic stress, as measured by cellular–cleaved caspase levels. 
In pilot studies, VEGF-C consistently lowered the generation 
of starvation-induced cleaved caspase by hLEC under several 
media conditions (Online Figure II). XylT2-deficient LECs 
(siXylT2; characterized by impaired glycan-chain initiation) 
were insensitive to VEGF-C during starvation (Figure 1D, right 
bar), whereas control-transfected hLEC consistently showed 
reduced apoptosis on starvation in the presence of VEGF-C 
(Figure 1D, siDS transfection control, left bar). Consistent with 
this, VEGF-C–dependent Akt phosphorylation in siXylT2-
targeted hLEC was reduced relative to control cells (Figure 
1E). When stimulated with a VEGF-C ligand that binds exclu-
sively to VEGFR-3 (VEGF-CCys156Ser),22 Akt phosphorylation 
in siXylT2-transfected cells was also blunted (Figure 1E, inset 
graph). We next examined how siNdst1 targeting might affect 
Akt phosphorylation in response to VEGF-CCys156Ser: similar re-
sults were found (Figure 1F), implying that VEGFR-3–specific 
Akt signaling is sensitive to altered glycan sulfation. Moreover, 
mitogen-activated pathway signaling (phospho-Erk1/2) in re-
sponse to VEGF-CCys156Ser was also sensitive to hLEC Ndst1 
deficiency (Figure 1G; it is noteworthy that in preliminary col-
lagen-attachment studies, hLEC attachment and spreading were 
somewhat slowed in Ndst1-deficient cells; data not shown).
Lymphatic-Specific Deficiency in the Sulfation 
of Heparan Sulfate Results in Altered VEGF-C–
Driven Tumor Lymphangiogenesis
To examine the effect of a lymphatic-exclusive mutation in 
heparan sulfate, we used mice bearing a conditional mutation 
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in Ndst1 driven by tamoxifen-inducible Cre under the control 
of the lymphatic-specific promoter Prox1 (Ndst1f/fProx1+/CreERT2 
mutants). In Prox1+/CreERT2Rosa26R reporter studies, inguinal 
and mediastinal lymph nodes showed a relatively high degree 
of Cre− LYVE-1 colocalization (Figure 2A, left), noted also 
in ear dermal lymphatics, albeit in a more patchy distribution 
Figure 1. Pan-endothelial mutation in heparan sulfate biosynthesis results in altered pathological lymphangiogenesis, lymphatic-
vascular apoptosis, and altered vascular endothelial growth factor-C (VEGF-C) signaling. A, Oil granulomas were generated in Ndst1f/
fTekCre+ mutants and Cre− littermates to examine lymphangiogenesis in this model. Sprouting of LYVE-1+ vessels (blue) in lesions was examined 
by immunohistology (bar=100 μm). Mean lymphatic vessel density graphed to right (n=4 mice/genotype; *P=0.003 for difference).  
B, Wound lymphangiogenesis after a full-thickness punch-type skin lesion was examined in Ndst1f/fTekCre+ mutants and Cre− controls. LYVE-1+ 
lymphatic vessels are shown (arrows) with wound edge (dotted line; W) and adjacent epithelial (Ep) surface. Mean lymphatic vessels per wound 
margin for each genotype graphed below (n=4 mutant and 5 wild-type mice; *P=0.002 for difference; bar=50 μm). C, Lymphangiogenesis was 
examined in a spontaneous breast carcinoma model. Tumor sections from mutant and control females show LYVE-1+ vessels in blue (bar=100 μm),  
with vessel density plotted (n=4 mice/genotype; *P=0.004 for difference). Tumor VEGF-C was confirmed (upper-right, immunofluorescence with 
IgG control; bar=20 μm). Lymphatic apoptotic index (quantity of dual terminal deoxynucleotidyl transferase dUTP nick-end labeling [TUNEL]/
LYVE-1+ vessels as a percentage of total LYVE-1+ vessels for each tumor) was examined: Photomicrographs show examples of blue LYVE-1+ 
vessels with dark TUNEL+ lymphatic nuclei (arrows) in 2 of the Cre+ mutant sections. Apoptotic index is graphed to right (*P<0.001 for difference; 
n=4 mice/group; left panels bar=20 μm; right panels bar=100 μm). D, Human lung lymphatic endothelial cells (hLEC) were tested for reduction 
in apoptosis as a result of mature VEGF-C exposure after a 6-h starvation period. In response to VEGF-C exposure, the ratio of cleaved- to total 
caspase-3 was examined by western, and normalized to densitometry for starved control-transfectant cells (starv baseline); with assays carried 
out in triplicate wells for each condition. Graph: response of xylosyltransferase 2 (XylT2)–transfected cells (siXylT2; right bar) compared with that 
of control hLECs transfected with mock/scrambled RNA (siDS; left bar; *P=0.02 for difference; average of 4 experiments). E, VEGF-C–induced 
phospho-Akt was examined by western in starved siXylT2-transfected vs control hLEC, with phospho/total Akt normalized and plotted relative 
to value for starved siDS cells (*P=0.05 for indicated difference in poststimulation [+] means; average of 4 experiments; representative blot 
shown). Inset graph shows response to a human VEGF-C form (VEGF-CCys156Ser), which binds exclusively to VEGFR-3. F, Effect of siNdst1 
targeting on Akt phosphorylation in response to VEGF-CCys156Ser (*P<0.01 for difference in means; average of 3 experiments). G, Effect of 
siNdst1 targeting on Erk1/2 phosphorylation in response to VEGF-CCys156Ser (*P=0.03 for difference in means; average of 3 experiments).
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(Figure 2A, right). With this in mind, we established sub-
cutaneous VEGF-C overexpressing Lewis lung carcinomas 
(LLC-VC) in the right flank of tamoxifen-induced Ndst1f/
fProx1+/CreERT2 mutant and wild-type (Ndst1f/fProx1−/CreERT2) lit-
termates. LYVE-1 staining showed robust lymphangiogenesis 
only at the tumor periphery in this model (F4/80 macrophage 
staining revealed a diffuse-tumor pattern, which decreased to-
ward the tumor periphery, with nearly complete non-overlap 
of F4/80 with LYVE-1 staining; Online Figure III). The tu-
mors showed no significant difference in size between mutant 
and wild-type groups (data not shown). Empty-vector con-
trol tumors (LLC-ev) were established in the opposite (left) 
flank of each mouse. In Cre− wild-type mice, LLC-VC tumors 
showed a significantly higher mean LVD than that of LLC-ev 
tumors (Figure 2B, graph, left bars), indicating a VEGF-C–
dependent boost in LVD caused by tumor-associated VEGF-C 
expression in wild-type mice (compare representative photo-
micrographs of LYVE-1 immunofluorescence on left of the 
panel set, for Cre− animals). However, among Cre+ mutants, 
LVD was not greater in LLC-VC tumors when compared with 
that of LLC-ev tumors (Figure 2B right panels and graph, 
right bars). The findings suggest that the inhibitory effect of 
lymphatic-targeted Ndst1 mutation on LVD in this model was 
specifically associated with VEGF-C–mediated lymphatic-
vessel growth.
To examine lymphatic proliferation in an orthotopic-tumor 
setting, LLC-VC cells were intravenously injected into Ndst1f/
fProx1+/CreERT2 mutants and Prox1−/CreERT2 controls. The mean 
quantity of LYVE-1/podoplanin double-positive LECs (as a 
percentage of total LECs) from lung digests 7 days post injec-
tion was reduced in mutants (Figure 2C), indicating an inhibi-
tory effect of mutation on total LECs purified from LLC-VC 
tumor-harboring lungs.
Phosphorylation of VEGFR-3 Is Sensitive to Altered 
Biosynthesis of Heparan Sulfate in Cultured 
Human LECs
Preliminary assessments of VEGF-C produced by cultured 
LLC-VC cells revealed unprocessed VEGF-C in the superna-
tants and lysates. The quantity of this species relative to post-
translationally processed, including mature, VEGF-C species 
produced by the tumors in vivo (which we confirmed by Western 
blotting) is unknown. Because unprocessed VEGF-C contains 
heparin-binding propeptide extensions,2,23 and because nonma-
ture forms of VEGF-C are variably secreted from tumors,24,25 
we first screened the degree to which pro–VEGF-C (a mixture 
of unprocessed and partially processed VEGF-C propeptides) 
is able to phosphorylate receptor tyrosine kinase receptors, in-
cluding VEGFR-3, in heparan sulfate–deficient versus control 
hLECs (Online Figure IV highlights the composition of pro–
VEGF-C separated on a silver-stained gel). Initially, in a highly 
sensitive receptor tyrosine kinase phospho array, inhibition 
Figure 2. A lymphatic-specific genetic deficiency in the 
sulfation of heparan sulfate results in altered vascular 
endothelial growth factor-C (VEGF-C)–driven tumor 
lymphangiogenesis. Reporter studies in Prox1+/CreERT2 
Rosa26R mice examined colocalization of Cre (X-gal positive 
staining) with LYVE-1+ vessels after tamoxifen induction.  
A, Lymph nodes (LNs) draining the lung (mediastinum) showed a 
high degree of colocalization (left), and dermal ear lymphatics 
(right) demonstrated patches of colocalization. B, Lewis lung 
carcinoma (LLC) cells that overexpress VEGF-C (LLC-VC) were 
used to establish subcutaneous tumors in the right flank of 
Ndst1f/f Prox1Cre+/ERT2 (n=4) mutant mice and Cre− littermate 
controls (n=4). Simultaneously, control LLC cells (LLC-ev) were 
injected into the left flank of the same animals to establish 
VEGF-C–negative control tumors. After 10 d, tumors were 
resected, and lymphangiogenesis was examined by LYVE-1 
immunofluorescence. Representative images show LYVE-1+ 
lymphatic endothelia (red) in tumor sections from mutants 
(right) and controls (left). Graph shows mean density of LYVE-1+ 
lymphatic vessels (±SD) in LLC-VC and LLC-ev tumors from 
Ndst1f/f Prox1Cre+/ERT2 mutant vs Cre− control littermates 
(*P=0.05 for the interaction of genotype with VC vs ev tumor 
status). In the mutant group, the difference in means was not  
significant. C, To examine tumor, VEGF-C–driven lymphatic 
proliferation in the lung, LLC-VC cells were intravenously injected into 
Ndst1f/f Prox1Cre+/ERT2 mutants (n=5) and Cre− (n=5) (Continued )
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Figure 2 Continued. controls. Mice were euthanized 7 d after 
injection: Tumor-containing lungs from each mouse were 
digested into a single-cell suspension, and LYVE-1+/podoplanin+ 
(double positive) LECs present in the digests were measured by 
flow cytometry. Representative panels are shown for Cre+ mutant 
and Cre− control mice; and averages (±SD) for both the groups, 
expressed as %total cells, are shown in graph to right (*P<0.001 
for the difference with wild-type [WT]).
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of hLEC heparan sulfate biosynthesis robustly blocked pro–
VEGF-C–mediated VEGFR-3 phosphorylation (Figure 3A), as 
well as VEGFR-2 phosphorylation. Although phosphorylation 
of both receptors seemed to be sensitive to the glycan altera-
tion, the baseline phosphorylation of VEGFR-3 on ligand stimu-
lation seemed to be markedly greater in this primary cell line, 
consistent with its lymphatic endothelial identity. Nevertheless, 
the marked sensitivity of VEGFR-2 phosphorylation to glycan 
targeting points to an additional role for heparan sulfate in fa-
cilitating VEGFR-2 activation in response to VEGF-C, remi-
niscent of its importance in VEGF-A signaling.26 The effect 
of glycan targeting on VEGFR-3 phosphorylation in response 
to pro–VEGF-C was also tested in a specific (albeit less sensi-
tive) ELISA-based phospho–VEGFR-3 assay (Figure 3B), with 
phosphorylation blockade that resulted from siXylT2 target-
ing. VEGFR-3 phosphorylation by mature VEGF-C was also 
significantly reduced in siXylT2-targeted hLEC (Figure 3C). 
Interestingly, siXylT2-inhibition of glycan-chain biosynthesis 
also inhibited receptor phosphorylation by a minimum recep-
tor-binding species of VEGF-C (Figure 3D) that excludes ba-
sic amino acids in the C terminus (L216–R227; which may 
contribute to a weak interaction of mature VEGF-C with hepa-
ran sulfate14), implying an important cell-autonomous role for 
the glycan in receptor activation.
Figure 3. Disruption of lymphatic heparan sulfate biosynthesis in primary human lymphatic endothelial cells (hLECs) results in 
reduced phosphorylation of vascular endothelial growth factor receptor-3 (VEGFR-3) in response to distinct VEGF-C species. A 
receptor screening format was used to assess how targeting heparan sulfate biosynthesis might alter VEGFR-3 activation in response 
to distinct VEGF-C species. A, In a preliminary multiple-receptor screen, cultured serum-starved hLEC transfected with either control/
scrambled RNA (siDS) or siXylT2 were stimulated with Pro–VEGF-C, and phosphorylation of growth receptors from poststimulation (vs 
unstimulated) cell lysates was measured using a receptor tyrosine kinase phospho array, which reports receptor phosphorylation (pair of 
dots) for all receptors captured from cell-lysate samples. The array for starved control (mock transfected) hLEC shows a weak phospho–
VEGFR-3 signal (upper-left slide; dot pair within box, with arrows also pointing to phospho–VEGFR-2 for reference). The array for control 
cells 15 min poststimulation with Pro–VEGF-C (siDS+ Pro–VEGF-C) is shown in the lower-left slide. Slides to the right show responses 
for baseline- vs stimulated siXylT2–transfected hLEC (dot pairs on corners of each slide are phosphotyrosine-positive controls.) 
Autophosphorylation occurred for a few other receptors at baseline, without a major response to Pro–VEGF-C: Those were Flt3 (dot pair 
immediately above VEGFR-3), VEGFR-1 (to left of VEGFR-2), Tie-2 (lower left), HGFR (hepatocyte growth factor receptor; immediately 
above/to right of Tie-2), and faintly visible EGFR (upper left). Signal values normalized to that of starved-control unstimulated cells are 
plotted on graph to right. A separate array repeated under identical conditions showed similar results. B, The ability of Pro–VEGF-C to 
phosphorylate VEGFR-3 in control- (siDS) or siXylT2-transfected hLEC was then exclusively carried out in a capture-ELISA format. Mean 
signal values normalized to that of control unstimulated cells (siDS and no VEGF-C) are plotted (*P=0.006 for interaction of siRNA status 
with VEGF-C stimulation response; average of 3 experiments). C, The same ELISA-based assay was used to examine the effects of hLEC 
xylosyltransferase 2 (XylT2) silencing on VEGFR-3 phosphorylation in response to stimulation with human mature VEGF-C, with control-
normalized signal values plotted on the graph (*P=0.006 for the interaction; average of 6 experiments). D, Responses were examined 
for stimulation by a short form of VEGF-C (T103-L216) that does not bind heparin, and contains the minimal receptor-binding domain 
A112-L215 (*P=0.01 for the interaction; average of 5 experiments).
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Sdc-4 Is a Dominant Proteoglycan Core Protein 
on Lymphatic Endothelium With Functional 
Significance in Pathological Lymphangiogenesis
We explored whether a dominant proteoglycan might pres-
ent heparan sulfate on the lymphatic cell surface. Although 
LECs were not easily purified from tumors, pathological 
primary LECs could be isolated from mesenteric oil granu-
loma/lymphangioma lesions,14,15 and they were examined 
for the repertoire of HSPG core proteins quantitative poly-
merase chain reaction. Sdc-4 was the dominantly expressed 
lymphatic cell-surface HSPG (Figure 4A, left graph). Cells 
did not express CD44v3 proteoglycan, known to be expressed 
by blood-vascular endothelia,27,28 although they did express 
perlecan, which is secreted into basement membranes, and 
which has been detected around proliferating and collecting 
lymphatics.29 The HSPGs expressed by svLEC, an immortal-
ized mouse mesenteric-lymphatic cell line, showed a similar 
profile (Online Figure V). It should be noted that we were able 
to measure a moderate increase in Sdc4 expression on Ndst1 
silencing in this cell line (Figure 4A, upper-right graph); 
Figure 4. Syndecan 4 is a dominant heparan sulfate proteoglycan (HSPG) in primary lymphatic endothelia, and genetic targeting 
of syndecan-4 results in altered pathological lymphangiogenesis. The genetic importance of proteoglycan core protein targeting was 
examined in pathological lymphangiogenesis. A, The repertoire of HSPG core proteins expressed by proliferating lymphatic endothelial 
cells (LECs) isolated from oil-granuloma lesions in mice was assessed by quantitative polymerase chain reaction (qPCR). RNA was 
isolated, reverse transcribed, amplified using gene-specific primers to each core protein, and quantified relative to expression of β-actin. 
Ct values from triplicate assays were used to calculate % expression. Given the unique expression profile of syndecans, with syndecan-4 
as a dominantly expressed HSPG, expression of the syndecan members was examined in the svLEC mesenteric LEC cell line in the 
setting of silencing of Ndst1 (siNdst1), with comparison to expression by control svLECs, transfected with random (scrambled duplex) 
RNA (siDS); with values in graph to upper right. B, Oil-granuloma lesions were induced in syndecan-4 knockout (Sdc4−/−) mice and wild-
type controls. Hematoxylin and eosin–stained sections of the lesions (left) were characterized by dense granuloma cell infiltrates (Gr) 
surrounding oil droplets (O), with lesions abutting the abdominal diaphragmatic (D) surface. Immunostaining for LYVE-1 revealed marked 
lesion-associated lymphangiogenesis in sections from wild-type mice, with lymphatic vessels (arrows, right photomicrographs; bar=100 
μm) shown in blue. Mean lymphatic vessel densities are graphed to the right (n=4 mice per genotype; *P=0.002 for difference). C, To 
assess the repertoire of proteoglycan core proteins expressed by other primary nonpathological LECs purified from the mouse as well as 
the effect of Ndst1 mutation on core protein expression, primary LECs were isolated from the lungs of Ndst1f/fTekCre+ mutants and Cre− 
littermates. RNA from purified LECs was processed (as in B) for quantitative PCR, and the expression of major HSPGs was quantified 
relative to that of β-actin (graph). Expression of the dominant core protein, again noted to be syndecan-4, seemed to be markedly 
upregulated in Ndst1-deficient LECs (light bars in graph). D, Expression was also examined using the same method for primary LECs 
isolated from the LNs of wild-type and Ndst1f/fTekCre+ mutants, with similar findings.
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however, the expression of the other syndecans did not change 
in that setting, with Sdc4 remaining the dominantly expressed 
lymphatic HSPG.
With this in mind, we generated oil granuloma/lymphangi-
oma lesions in Sdc-4 null (Sdc4−/−) mice, and noted reduced le-
sion LVD (Figure 4B). Lymphangiogenesis in Sdc4(−/−) Ndst1f/
fTekCre+ double mutants examined using this pathological 
model was not significantly reduced in comparison with that 
in Sdc4(−/−)Ndst1f/fTekCre− littermates (data not shown), sug-
gesting that Sdc-4 likely serves as a quantitatively dominant 
functional scaffold for lymphatic cell-surface heparan sulfate, 
playing a critical role in pathological lymphatic mitogen re-
sponses. We also measured HSPG core protein expression in 
nonpathological LECs purified from the lung (Figure 4C) or 
lymph nodes (Figure 4D) of wild-type and Ndst1f/fTekCre+ mu-
tants. Sdc-4 was not only the dominant HSPG but was also dis-
proportionately upregulated in the setting of Ndst1 deficiency, 
indicating that targeting the sulfation of lymphatic heparan sul-
fate upregulates major HSPG core protein expression.
Sdc-4 Specifically Associates With VEGFR-3 in 
Response to VEGF-C in Human LECs in a Heparan 
Sulfate–Dependent Manner and Mediates VEGF-
C–Dependent Signaling
We asked whether Sdc-4 might associate with VEGFR-3 (as a 
possible ternary complex) in hLECs on VEGF-C stimulation. 
In human LECs, we previously found that expression of Sdc2 
was somewhat greater than that of Sdc4.16 (as a reference, for 
primary human dermal microvascular blood-endothelial cells, 
Sdc4 seems to be the dominantly expressed transmembrane 
HSPG; Online Figure VI). Core protein studies also revealed 
that the dominant cell-surface HSPGs on hLECs were Sdc-2 
and Sdc-4 (as assessed by HSPG core protein blotting; Online 
Figure VII). Nevertheless, proximity ligation analysis (PLA) re-
vealed that resting starved hLEC (ie, pre-VEGF-C stimulation) 
are characterized by a significant degree of Sdc-4–VEGFR3 
association at baseline. Exposure to mature VEGF-C strik-
ingly increased Sdc-4–VEGFR-3 association, whereas Sdc-2–
VEGFR-3 association under identical conditions was minimal 
(Figures 5A and 5B, left side of graph; hLEC). The magnitude 
of Sdc-1–VEGFR-3 association (not shown) was comparable 
with that of Sdc-2–VEGFR-3, with signals remaining <10% 
that of baseline Sdc-4–VEGFR-3 signal. Examination of Sdc-
4–VEGFR-3 PLA in the mouse oil granuloma–derived svLEC 
line also revealed a marked rise in Sdc-4–VEGFR-3 asso-
ciation on VEGF-C exposure (quantified in Figure 5B, right 
graph; svLEC). In separate experiments examining VEGFR-2, 
stimulation of hLECs with mature VEGF-C did not lead to en-
gagement of Sdc-4 with VEGFR-2 (Figure 5C; representative 
panels), suggesting that Sdc-4 serves as a specific coreceptor for 
VEGFR-3. To further explore mechanism, we found that forma-
tion of Sdc-4–VEGFR-3 complexes on VEGF-C treatment was 
sensitive to hLEC pretreatment with heparanase (Figure 5D), 
suggesting that lymphatic heparan sulfate is required for stabi-
lizing the proteoglycan-receptor complex on ligand exposure.
With these findings in mind, we asked whether Sdc-4 defi-
ciency might affect signaling by mature VEGF-C: phosphoryla-
tion of the mitogen-pathway intermediate Erk1/2 was sensitive 
(Figure 5E; representative immunoblot shown to right). As a 
receptor-signaling control, Erk1/2 phosphorylation in response 
to VEGF-C was comparatively sensitive to VEGFR-3 deficiency, 
and somewhat less sensitive to VEGFR-2 deficiency (Figure 5E, 
upper-right representative histogram). These Erk1/2 signaling 
findings further prompted us to use a commercial phosphosig-
naling array to examine patterns in VEGF-C–dependent activa-
tion of other lymphatic endothelial mitogen-activated protein 
kinase–associated intermediates in the setting of Sdc-4 silencing. 
In addition to replicating the pattern we found in Erk phosphory-
lation in the array (with predominantly Erk1 showing a blunted 
response to VEGF-C stimulation in the setting of Sdc-4 defi-
ciency), we also noted inhibition of a second mitogen-activated 
protein kinase intermediate (p38β) along with associated inhibi-
tion of HSP27 phosphorylation in the same setting (Figure 5F, 
with quantified responses below). The array also demonstrated 
concomitant reduction in VEGF-C–dependent Akt2 and TOR 
activation, which corroborates the original findings in Figure 1, 
showing altered lymphatic endothelial survival signaling as a re-
sult of targeting the glycan chain.
Discussion
We examine herein the genetic importance of lymphatic 
heparan sulfate and that of a key proteoglycan core protein in 
pathological lymphangiogenesis. Genetic targeting of the gly-
can impairs pathological lymphangiogenesis in vivo and lym-
phatic mitogen and survival signaling and phosphorylation 
of VEGFR-3 in response to VEGF-C. We also demonstrate 
the genetic importance of Sdc-4 as a key HSPG that scaffolds 
heparan sulfate on the lymphatic surface, and propose that it 
functions as a major coreceptor in VEGF-C–mediated patho-
logical lymphangiogenesis.
In Ndst1f/fTekCre+ mutants, Ndst1 inactivation under the 
Tek-promoter generates a pan-endothelial mutation, and Ndst1 
expression in LECs purified from mutants was markedly re-
duced. Lymphatic signaling via VEGF-C/VEGFR-3 seemed 
to contribute to lymphatic proliferation in both oil granuloma/
lymphangioma models21 (Figure 1A) as well as transgenic car-
cinoma (Figure 1C) models. Although altering lymphatic Ndst1 
inhibits VEGF-C–dependent sprouting and growth signaling in 
vivo, other heparin-binding growth factors such as VEGF-A, 
fibroblast growth factor-2, or PDGF may also contribute to lym-
phatic growth and remodeling. Nevertheless, deficiency in the 
glycan not only altered VEGF-C–mediated protection of pri-
mary LECs from apoptotic stress (Figure 1C, bottom) but con-
sistent with this, Erk- and Akt-mediated signaling in primary 
hLECs was also inhibited in mutants (Figure 1E through 1G). 
Pathological blood-vascular angiogenesis seemed to be altered 
in such pan-endothelial Ndst1 mutants, consistent with previous 
work.10 Although an indirect effect of the blood-vascular muta-
tion on lymphangiogenesis is possible in the setting of patho-
logical angiogenesis, findings using high-specificity lymphatic 
gene targeting in vivo (discussed below) together with ex-vivo 
and cell-based work herein point to an important and direct role 
for lymphatic-specific heparan sulfate in VEGF-C–mediated 
VEGFR-3 activation.
To stringently target heparan sulfate in VEGF-C–mediated 
lymphatic-specific remodeling, we used a VEGF-C expressing 
lung carcinoma model on a genetic background wherein Ndst1 
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Figure 5. Proteoglycan-dependent signaling and complexing of syndecan-4 (Sdc-4) with vascular endothelial growth factor-3 
(VEGFR-3) on VEGF-C stimulation. A, Dynamic association of VEGFR-3 with 2 highly expressed heparan sulfate proteoglycans (Sdc-2 
and Sdc-4) on the lymphatic cell surface was tested in response to mature VEGF-C on serum-starved human lung lymphatic endothelial 
cells (hLECs) via proximity ligation assay (PLA). Proximity of Sdc-4 to VEGFR-3 is shown at baseline (lower right; PLA signal, red dots) 
and after stimulation with mature VEGF-C (upper right; DAPI [4',6-diamidino-2-phenylindole] nuclei in blue; bar=50 μm). Left, PLA for 
Sdc-2 and VEGFR-3. B, Split-graph on left shows mean PLA signals for hLECs from multiple experiments (n=3 for Sdc-2 and n=5 for 
Sdc-4; ±SEM), normalized to mean for Sdc-4/VEGFR-3 association at baseline (**P=0.03 for difference between baseline and +VEGF-C 
means). Split-graph to right shows mean Sdc-4/VEGFR-3 PLA signals for mouse svLECs (n=4 experiments; ±SEM), normalized to 
baseline (no VEGF-C; **P=0.03 for difference between baseline and +VEGF-C means). C, PLA to examine Sdc-4/VEGFR-2 association 
was carried out ± VEGF-C: representative photomicrographs shown. D, To examine the importance of heparan sulfate, PLA signals in 
hLECs treated ± heparinase (destroys heparan sulfate chains) were quantified, normalized to baseline for Sdc-4/VEGFR-3, and graphed 
(*P=0.02 for interaction of ± heparinase status with VEGF-C stimulation response; average of 5 experiments). E, The effect of siRNA 
targeting of Sdc-4 Sdc4 (siSdc4) on Erk phosphorylation in response to mature VEGF-C was examined in cultured hLEC (*P=0.04 for 
difference; average of 4 experiments; representative blot at lower right). Upper-right inset graph shows representative histogram of effect 
of siRNA targeting of VEGFR-3 or VEGFR-2 on Erk phosphorylation in the same cells as a mitogen receptor-signaling control. F, Lysates 
from control (siDS) or siSdc4 hLECs pre-/post–VEGF-C stimulation were applied to a phosphosignaling array reporting phosphorylation 
of several mitogen-activated protein kinase and survival-signaling intermediates (as dot pairs) on the membranes. Arrays for control cells 
(siDS) pre-/post–VEGF-C are shown to left. Slides to right show corresponding signals for siSdc4-transfected hLEC. A box is placed 
around P-Erk1 for reference, showing marked stimulation in control hLEC with blunted response in Sdc-4–deficient cells, resembling 
western pattern in D. Other notable blunted VEGF-C responses in Sdc4-deficient cells (graphed below) included p38β (black arrow), 
survival pathway intermediates (Akt2 and TOR; red arrows); and the heat-shock protein HSP27 (arrowhead).
0
1
2
3
4
5
6
7
VEGF-C: -     + -     +
Syndecan-2 Syndecan-4
N
or
m
al
iz
ed
 S
yn
de
ca
n-
VE
G
FR
-3
  P
LA
 S
ig
na
lB
**
A
Syndecan-4 - VEGFR-3
Baseline
Syndecan-4 - VEGFR-3
+ VEGF-C
Syndecan-2 - VEGFR-3
+ VEGF-C
Syndecan-2 - VEGFR-3
Baseline
C
Syndecan-4 - VEGFR-2
Baseline
Syndecan-4 - VEGFR-2
+VEGF-C
3.0
2.0
1.0
0
*
siDS siSdc4
        +        -     +
E
VEGF-C:
 
Ph
os
ph
o-
Er
k 
No
rm
al
ize
d 
 
 
 
 
 
 
 
 
 
 
 
 
 
to
 s
iD
S 
Co
nt
ro
l
p-Erk
Total Erk
siDS siSdc4
VEGF-C: -      +      -      +
kD
44/42
44/42
3.0 
1.0 
2.0 
siVE
GFR
-2 siDS
-    +        -     +       -     +VEGF-C:
4.0 
5.0 
 
 
 
 
 
N
or
m
al
iz
ed
 
ph
os
ph
o-
/T
ot
 E
rk
siVE
GFR
-3 
0
1
2
3
VEGF-C: -        + -       +
+Heparinase
Sy
nd
ec
an
-4
 - 
VE
G
FR
-3
  
 
N
or
m
al
iz
ed
 P
LA
 S
ig
na
l
- Heparinase
4
*
D
-     +
Syndecan-4
(hLEC) (svLEC)
F    siDS
P-Erk1
P-HSP27
P-p38β
P-TOR
P-Akt2
P-Erk1
    siDS + VEGF-C
    siSdc4
    siSdc4 + VEGF-C
   
N
or
m
al
iz
ed
 
P
ho
sp
ho
-S
ig
na
l
siSdc4siDS
3.0 
1.0 
2.0 
-  +   -  + VEGF-C:
4.0 
5.0 
siSdc4siDS
-  +   -  + 
siSdc4siDS
-  +  -  + 
p38β mTOR HSP27
3.0 
1.0 
2.0 
4.0 
5.0 
**
Johns et al  Proteoglycan Coreceptor for Lymphangiogenesis  219
is specifically inactivated in lymphatic endothelium through 
the Prox1+/CreERT2 transgene. The findings point to the genetic 
importance of appropriately sulfated heparan sulfate in medi-
ating the action of VEGF-C on lymphatic endothelium in vivo 
(Figure 2B). It is possible that nonmature forms of VEGF-C 
produced by this or other neoplastic cell lines24 may be more 
sensitive to the effects of tumor-lymphatic Ndst1 mutation on 
VEGFR-3 activation because such species have a greater af-
finity for heparan sulfate than shorter (eg, mature) forms of 
VEGF-C. This may have pathophysiological importance in neo-
plasia, where nonmature forms of VEGF-C may play important 
roles in tumor-lymphatic remodeling, with possibly additional 
regulation through binding to HSPGs secreted into matrix (eg, 
perlecan). It is noteworthy that the predominant species present 
in pro–VEGF-C used in Figure 3A and 3B (ie, 29/31-kD pro-
peptide; Online Figure IV) may compete with other species for 
VEGFR-3 binding,30 and thus contribute to negative regulation. 
This may explain the relatively weak stimulation by pro–VEGF-
C in Figure 3B. Nevertheless, siXylT2 targeting resulted in 
complete inhibition of VEGFR-3 phosphorylation in this setting, 
possibly as a result of greater heparan sulfate binding by unpro-
cessed and propeptide VEGF-C species. In tumors, this binding 
may allow for greater presence of propeptide VEGF-C on the 
lymphatic cell surface, where proteases (eg, ADAMTS3 tethered 
to endothelium30) may yield local release of mature VEGF-C. 
Interestingly, VEGFR-3 activation by a nonheparin-binding short 
form of VEGF-C remained sensitive to altered heparan sulfate 
biosynthesis (Figure 3D), pointing to the importance of intact 
lymphatic cell-surface heparan sulfate in VEGFR-3 activation/
function. This is reminiscent of altered VEGFR-2 responses to 
a key nonheparin-binding form of VEGF-A (ie, VEGF121) when 
endothelial heparan sulfate is genetically altered.26
A variety of proteoglycans may tether heparan sulfate to 
the lymphatic cell surface or pericellular matrix.8 Although we 
found abundant expression of Sdc-4 on lymphatic endothelium 
(Figure 4), a model limitation is that Sdc4−/− mutation is not tissue 
specific. However, pairing the genetic importance of appropri-
ate glycan sulfation in lymphangiogenesis with the finding that 
Sdc-4 forms a specific and robust association with VEGFR-3 
in response to VEGF-C (Figure 5A through 5C) suggests that 
Sdc-4 plays a critical role in VEGFR-3–mediated lymphatic 
growth. Importantly, the VEGFR-3–specific mitogen response 
to VEGF-C seems to be glycan dependent (Figure 5D) and re-
duced in the setting of Sdc-4 deficiency. In light of the altered 
signaling with this mutation (Figure 5E), the collective findings 
suggest that lymphatic-endothelial Sdc-4 deficiency (or Ndst1 
deficiency, which would affect glycans on all HSPGs, including 
the dominant membrane-bound pool of Sdc-4) results in both al-
tered mitogen-pathway as well as altered survival/Akt signaling 
(Figure 1F and 1G as well as Figure 5E). Although other HSPGs 
could theoretically partially compensate through the collective 
actions of their glycans to partially support mitogen-pathway 
Figure 6. Schematic diagram showing functions of the lymphatic endothelial heparan sulfate proteoglycan syndecan-4 at the cell 
surface on ligand stimulation by vascular endothelial growth factor-C (VEGF-C). In 1 pathway (A), introduction of VEGF-C induces 
association between the growth factor (VEGF-C), proteoglycan (syndecan-4), and receptor (VEGFR-3), wherein the proximity of syndecan-4 
to the receptor as well as binding of the ligand is stabilized by the glycan chain. This coreceptor function is necessary for efficient receptor 
phosphorylation and activation, leading to mitogen-activated cell growth and survival signaling. Absence of the proteoglycan, or lack of an 
appropriately sulfated glycan chain, is associated with impaired lymphatic growth signaling in response to VEGF-C. An alternative pathway 
(B) highlighting cell-autonomous ligand-depot functions of lymphatic endothelial heparan sulfate illustrates the ability of the appropriately 
sulfated glycan chain to bind VEGF-C, making it available for receptor binding via VEGFR-3 receptors on the cell surface. This may 
eventually lead to further#8232;syndecan-4–VEGFR-3 proximity and ternary complex formation (bottom). The depot function of heparan 
sulfate for species of VEGF-C with greater heparin-binding affinity (ie, preproteolytically processed VEGF-C > mature VEGF-C) may be 
particularly important in regulating availability of those species for interaction with receptor at the cell surface. Regardless, the glycan chain 
ultimately is necessary to stabilize a proteoglycan coreceptor complex that optimizes cell signaling (bottom, via pathway B).
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responses in Sdc-4–deficient lymphatic endothelium, the si-
lencing of this unique proteoglycan seems to critically alter 
lymphatic VEGFR-3–dependent growth/survival signaling and 
possibly pathways that affect cytoskeletal rearrangement during 
pathological lymphangiogenesis. Interestingly, the cooperative 
activation of Erk1/2 along with p38 mitogen-activated protein 
kinase and HSP27 (which we found altered in VEGF-C–treated 
Sdc-4–deficient primary LECs; Figure 5F) has been reported to 
play an important role in endothelial actin cytoskeletal reorgani-
zation in response to VEGF-A, with known inhibition of HSP27 
phosphorylation in response to several angiogenesis-pathway 
inhibitors.31–33 The findings suggest that VEGF-C–mediated acti-
vation of this pathway during lymphatic endothelial cytoskeletal 
remodeling may also be important, and sensitive to alterations 
in Sdc-4 as a coreceptor. More generally, the findings point to a 
critical coreceptor role for the dominant lymphatic HSPG Sdc-4 
in pathological lymphangiogenesis.
Figure 6 shows a model to illustrate the functional impor-
tance of these molecules in lymphatic receptor functions: in 1 
mode, glycans on the lymphatic surface may serve in a cell-au-
tonomous role as a depot for VEGF-C that, in turn, may affect 
the availability for VEGFR-3 interactions (Figure 6, pathway 
B to right). The degree of this may depend on the species of 
VEGF-C available and the heparin-binding affinity of that spe-
cies; with signaling by the different species variably sensitive 
to genetic absence of the glycan on the cell surface (Figure 3B 
through 3D). However, the glycan seems to play an essential 
role in stabilizing a ternary complex that mediates proximity of 
the proteoglycan core protein to the growth receptor (Figure 5), 
with the HSPG thus serving as a coreceptor (Figure 6, bottom). 
This may occur either simultaneously when ligand becomes 
available (Figure 6, pathway A), or step-wise via initial con-
centration and availability of the ligand for receptor-binding 
events before complex stabilization (Figure 6, 2-step pathway 
B). Conceptually, in considering distinct vascular beds, this 
leaves the possibility of proteoglycan core proteins other than 
Sdc-4 that could depend on the common glycan (heparan sul-
fate) in mediating receptor activation in response to VEGF-C. 
However, in the proof-of-concept studies shown here, we have 
demonstrated important roles for heparan sulfate expressed on 
lymphatic endothelial Sdc-4.
These findings may have translational potential. In tu-
mors, although alterations in LVD might not primarily affect 
primary tumor size, the alteration in lymphatic conduit may 
reduce the potential for lymphatic metastasis; and in many in-
vasive tumors, upregulation of VEGF-C as well as the expres-
sion of other heparin-binding growth factors and cytokines 
contributes to tumor lymphangiogenesis.2,6,34
 Considering also 
the roles of both Ndst1 (appropriate glycan chain sulfation) 
and Sdc-4 in the proliferation of lymphatic vessels as well as 
the mechanistic importance of Sdc-4 as a coreceptor for lym-
phatic signaling (Figure 6), approaches that target the expres-
sion of these molecules in the lymphatic microenvironment 
may serve as new selective strategies to modulate critical lym-
phatic remodeling in disease.
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What Is Known?
•	 Lymphatic-vascular remodeling in disease states such as neoplasia or 
inflammation may facilitate important downstream pathophysiological 
events, such as lymphatic metastasis or organ fibrosis, among other 
consequences depending on the tissue and disease process.
•	 Although the major lymphatic vascular mitogen vascular endothelial 
growth factor-C (VEGF-C) is critical in driving pathological lymphangio-
genesis primarily through the activation of the major lymphatic recep-
tor VEGFR-3, coreceptors that critically regulate ligand and receptor 
activation are poorly understood.
•	 Cell-surface proteoglycans displaying sulfated carbohydrate chains 
known as heparan sulfate are known to play key roles in endothelial 
growth factor binding and receptor signaling, although the genetic im-
portance and function(s) of these molecules in lymphatic remodeling 
in vivo remain unknown.
What New Information Does This Article Contribute?
•	 The sulfation of heparan sulfate on lymphatic endothelium is important 
in mediating the actions of VEGF-C on lymphatic endothelial growth in 
pathological models in vivo.
•	 Syndecan-4 is a major heparan sulfate proteoglycan expressed on 
lymphatic endothelium, and it serves as a novel coreceptor for lym-
phatic VEGFR3 signaling, forming a glycan-dependent complex with 
ligand and receptor on VEGF-C stimulation.
•	 Syndecan-4 deficiency results in reduced pathological lymphangio-
genesis and reduced VEGFR-3 mitogen signaling in primary lymphatic 
endothelial cells, introducing a novel mode of biological modulation 
and possibly therapeutic targeting.
The process of lymphangiogenesis plays critical roles in the path-
ological progression of several important diseases. These include 
metastasis-promoting lymphatic remodeling in cancer, lymphatic 
proliferation associated with lymphagioleiomyomatosis, or fibrotic 
progression in idiopathic fibrosis and renal tubulointerstitial dis-
ease, among others. Overexpression of VEGF-C in the lymphatic 
microenvironment of these disorders is a central requirement, 
and growth signaling primarily through the cognate lymphatic 
VEGFR-3 receptor plays a critical molecular role. We report the 
genetic importance of a novel glycan coreceptor for pathologi-
cal VEGF-C–dependent lymphangiogenesis in vivo. Mechanistic 
work points to important roles for appropriately sulfated lym-
phatic heparan sulfate in mediating Akt- and Erk-dependent 
lymphatic signaling as well as activation of lymphatic endothelial 
VEGFR-3 by multiple VEGF-C species. We also discovered that 
syndecan-4 is the major lymphatic heparan sulfate proteoglycan 
involved in mediating lymphatic VEGF-C–VEGFR-3 complex for-
mation and signaling in a manner that critically depends on its 
glycan chains, and we propose a novel role for heparan sulfate 
proteoglycans in mediating this biological process. The findings 
may guide development of novel glycan-biosynthesis inhibitors 
or proteoglycan-targeting strategies to inhibit carcinoma spread, 
fibrosis in a variety of inflammatory states, or conditions where 
lymphangiogenesis contributes to pathological progression.
Novelty and Significance
